These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34224755)

  • 1. Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends.
    Kadkhoda J; Akrami-Hasan-Kohal M; Tohidkia MR; Khaledi S; Davaran S; Aghanejad A
    Int J Biol Macromol; 2021 Aug; 185():664-678. PubMed ID: 34224755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring Binding Kinetics of Antibody-Conjugated Gold Nanoparticles with Intact Cells.
    Yin L; Yang Y; Wang S; Wang W; Zhang S; Tao N
    Small; 2015 Aug; 11(31):3782-8. PubMed ID: 25865036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy.
    Shah P; Shende P
    Curr Cancer Drug Targets; 2022; 22(1):31-48. PubMed ID: 34872476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the tumor microenvironment with nanoparticles.
    Miao L; Huang L
    Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.
    Guo YY; Huang L; Zhang ZP; Fu DH
    Curr Med Sci; 2020 Jun; 40(3):463-473. PubMed ID: 32681251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-cyclodextrin based dual-responsive multifunctional nanotheranostics for cancer cell targeting and dual drug delivery.
    Das M; Solanki A; Joshi A; Devkar R; Seshadri S; Thakore S
    Carbohydr Polym; 2019 Feb; 206():694-705. PubMed ID: 30553374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
    Kamel HFM; Al-Amodi HSAB
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    Colombo M; Rizzuto MA; Pacini C; Pandolfi L; Bonizzi A; Truffi M; Monieri M; Catrambone F; Giustra M; Garbujo S; Fiandra L; Corsi F; Prosperi D; Mazzucchelli S
    Bioconjug Chem; 2018 Nov; 29(11):3817-3832. PubMed ID: 30350574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Evaluation of Protein-Based Nanoparticles for Stable Delivery of Small Interfering RNA.
    Suresh D; Jenkins B; Zambre A; Upendran A; Kannan R
    J Biomed Nanotechnol; 2020 Jul; 16(7):1169-1181. PubMed ID: 33308383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines in Diagnosis and Treatment of Cancer: An Update.
    Haider N; Fatima S; Taha M; Rizwanullah M; Firdous J; Ahmad R; Mazhar F; Khan MA
    Curr Pharm Des; 2020; 26(11):1216-1231. PubMed ID: 32188379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-responsive antibodies for therapeutic applications.
    Klaus T; Deshmukh S
    J Biomed Sci; 2021 Jan; 28(1):11. PubMed ID: 33482842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
    Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
    ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
    Du JZ; Li HJ; Wang J
    Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-based conjugates for tumor-targeted drug delivery and imaging.
    Saravanakumar G; Deepagan VG; Jayakumar R; Park JH
    J Biomed Nanotechnol; 2014 Jan; 10(1):17-31. PubMed ID: 24724496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted nanoparticles for cancer therapy.
    Fay F; Scott CJ
    Immunotherapy; 2011 Mar; 3(3):381-94. PubMed ID: 21395380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.